tbuckley/cabot-search huggingface dataset:
Abstract #LB-263: Elevated levels of circulating folate receptor alpha in women with ovarian cancer.
Authors: Eati Basal, Guiti Eghbali-Fatourechi, Kimberly Kalli, Lynn Hartmann, Karin Goodman, Ellen Goode, Barton Kamen, Philip Low, Linda Kelemen, Keith Knutson
Journal: Cancer Research (2009)

Despite a relatively low incidence rate, ovarian cancer is the fifth leading cause of cancer deaths and it has the highest mortality rate of all gynecologic malignancies among US women. The high mortality rate could potentially be reduced if a marker of early detection were available for routine screening. The folate receptor alpha (FR\#945;) is one seemingly logical choice for a biomarker because of its prevalent overexpression (~95%) in ovarian cancer and its relatively exclusive expression in only a few normal healthy tissues. In a prior recent study, it was observed that patients with ovarian cancer had elevated serum levels of a protein that bound to a FR\#945;-specific monoclonal antibody relative to control healthy individuals. Although it was not shown that the protein detected was definitively FR\#945;, that work did suggest that FR\#945; may be a useful biomarker of ovarian cancer. Thus, in the current study, the goal was to determine whether ovarian cancer patients (n=30) had elevated serum levels of a fully functional intact FR\#945; compared to matched healthy controls (n=30). Circulating FR\#945; levels in serum were analyzed by two methods; 1) immunoprecipitation followed by immunoblotting and semi-quantitative band intensity analysis or 2) a radiolabeled folic acid-based micro-filtration binding assay. Using the immunoassay, we observed that levels of circulating FR\#945; were significantly higher in serum of ovarian cancer patients as compared to matched control subjects (14 ± 8 au vs. 7 ± 5 au, p  Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr LB-263.
A 4-year prospective evaluation of protocols to improve clinical outcomes for patients with lymphangioleiomyomatosis in a national clinical centre
Authors: Janet Bee, Rupesh Bhatt, Ian McCafferty, Simon R Johnson
Journal: Thorax (2015)

Lymphangioleiomyomatosis (LAM) is a rare multisystem disease. Progressive airflow limitation, pneumothorax and angiomyolipoma-related bleeding are major morbidities. As treatments are available for these complications, we prospectively audited loss of FEV<sub>1</sub> (ΔFEV<sub>1</sub>), pneumothorax and angiomyolipoma bleeding against clinical standards over 4 years at the UK Clinical Centre. ΔFEV<sub>1</sub> for these patients is lower than previously reported and rates of pneumothorax and angiomyolipoma haemorrhage are low. This suggests that real-time analysis of clinical data with targeted interventions can reduce morbidity in LAM. These measures could be applied as quality standards to compare the emerging LAM clinical networks worldwide.
Abstract 18686: Association of Obesity Susceptibility Gene Variants With Cardiometabolic Phenotypes in Morbid Obesity
Authors: Sabine Fenk, Marissa Koehler, Christina Strack, Ute Hubauer, Judith Zeller, Margareta Manka, Christine Meindl, Martina Zimmermann, Marcus Fischer, Andrea Baessler
Journal: Circulation (2014)

Introduction: Genome-wide association studies (GWAs) have identified several gene variants strongly associated with increased body mass index (BMI) and obesity. However, their association with the cardiometabolic consequences of obesity is unclear. We performed a study of 40 validated variants recently identified in two large metaanalysis GWAS and analyzed their association with related cardiovascular and metabolic traits of severe obesity. Methods: Genotyping was performed in 320 deeply-phenotyped obese subjects (mean BMI 41±9 kg/m2, aged 44±12 years), participating in a standardized weight reduction program. Anthropometric parameters, parameters of glucose/insulin metabolism, oxidative stress and early atherogenesis, adipokines, adhesion molecules, apolipoproteins, cardiac function and structure, intima media thickness and arterial elasticity were assessed standardized after 12h fast. Results: The transmembran protein TMEM18 rs939583 variant was significantly related to several parameters of adiposity (i.e. BMI β-estimate 1/2 risk alleles vs. no risk allele: 3.7±2.2/ 5.5±1.9, p=0.0009), epicardial fat thickness (p=0.023), insulin (p=0.002), fasting glucose (p=0.007), HOMA-IR (p=0.0008), and leptin (p=0.008) levels, systolic (p=0.007) and diastolic (p=0.009) blood pressure, arterial hypertension (frequency in subjects with 0/1/2 risk allele(s): 14/30/46%, p=0.001), and the metabolic syndrome (29/29/48%, p=0.029). Moreover, the BDNF rs10767664 variant was significantly associated with ApoA1, ApoA2, HDL cholesterol and soluble CD40L levels. Conclusion: TMEM18 and BDNF variants increased the risk of metabolic syndrome components, probably through their effect of abdominal obesity. However, several gene variants that have been found to be associated with BMI with small effects in large scale GWAS, did not seriously alter obesity related cardiometabolic traits.
Immunological predictors of overall survival in treatment naïve metastatic pancreatic cancer patients
Authors: Matthew R Farren, Thomas Mace, Susan Geyer, Sameh Mikhail, Christina Wu, Kristen Ciombor, Sanaa Tahiri, Daniel Ahn, Anne Noonan, Miguel Villalona-Calero, Tanios Bekaii-Saab, Gregory Lesinski
Journal: Journal for ImmunoTherapy of Cancer (2015)

Meeting abstracts Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that has a 5-year survival rate of less than 7% and is ultimately refractory to most treatments. An assessment of immunologic factors relevant to disease has not been performed in a comprehensive manner for treatment
Liposomal vincristine in relapsed non-Hodgkin's lymphomas: Early results of an ongoing phase II trial
Authors: A.H. Sarris, F. Hagemeister, J. Romaguera, M.A. Rodriguez, P. McLaughlin, A.M. Tsimberidou, L.J. Medeiros, B. Samuels, O. Pate, M. Oholendt, H. Kantarjian, C. Burge, F. Cabanillas
Journal: Annals of Oncology (2000)
Oral Hydration As a Post-Hydration Method for Cisplatin (Cddp) Administration in Patients with Lung Cancer: a Prospective Multicenter Trial
Authors: H. Horinouchi, K. Kubota, A. Miyanaga, Y. Minegishi, S. Takeuchi, S. Nakamichi, A. Gemma, F. Kurimoto, J. Sudo, Y. Yamane, H. Tsuzuki, H. Sakai, H. Utsumi, K.S. Sunami, H. Mizugaki, S. Kanda, Y. Fujiwara, H. Nokihara, N. Yamamoto, T. Tamura
Journal: Annals of Oncology (2014)
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ
Authors: Mathias Worni, Igor Akushevich, Rachel Greenup, Deba Sarma, Marc D. Ryser, Evan R. Myers, E. Shelley Hwang
Journal: JNCI Journal of the National Cancer Institute (2015)

Background:Impact of contemporary treatment of pre-invasive breast cancer (ductal carcinoma in situ [DCIS]) on long-term outcomes remains poorly defined. We aimed to evaluate national treatment trends for DCIS and to determine their impact on disease-specific (DSS) and overall survival (OS).
MIBG scoring as a prognostic indicator in patients with stage IV neuroblastoma: A COG study.
Authors: G. A. Yanik, M. T. Parisi, A. Naranjo, K. K. Matthay, W. B. London, P. W. McGrady, S. G. Kreissman, B. L. Shulkin
Journal: Journal of Clinical Oncology (2010)

9516 Background: Over the past 2 decades, radiolabeled metaiodobenzylguanidine (mIBG) has proven to be a highly sensitive and specific marker for the detection of primary and metastatic neuroblastoma. Recently, a semiquantitative mIBG scoring method (Curie score) has been developed. The aim of this study was to correlate mIBG score with outcome. Methods: Newly diagnosed patients (pts) with stage 4 neuroblastoma enrolled on COG A3973 were examined. MIBG scans were evaluated at the time of diagnosis (280 pts), post-induction (274 pts), post-transplant (203 pts), and upon completion of biotherapy (99 pts). Patients with non-mIBG avid disease at diagnosis were excluded. For each time point, mIBG scans were evaluated at 10 different anatomic sites. Scans were read by 2 observers, using a semiquantitative scoring method. Individual sites were scored 0-3, based upon extent of disease at each site. Absolute scores (cumulative score from each time point) and relative scores (absolute to initial score ratios) were correlated with event free survival (EFS) and overall survival (OS). Results: The median Curie score at diagnosis was 12 (range 1-30). There was no correlation between Curie score at diagnosis and EFS. In contrast, pts with a Curie score > 5 following induction therapy had a significantly worse EFS when compared to those with a score ≤ 5 (3 yr EFS: 8.3 ± 4.6% vs 41.5 ± 3.5%, p < 0.0001). The presence of mIBG avid disease in either the T or L-spine, chest, pelvis or distal lower extremities post-induction was associated with 3-yr EFS < 15%. Curie scores (0 vs > 0) post-induction had a greater impact in pts with MYCN amplified tumors (3 yr EFS: 45.2 ± 7.0% vs 15.0 ± 8.0%) than those with MYCN non-amplified disease (3 yr EFS: 45.4 ± 5.8% vs 35.9 ± 6.8%). Patients with Curie scores > 0 post-transplant had a 3-yr EFS of 28.6 ± 6.5%, compared to 45.2 ± 4.6% for those with a Curie score of 0 post-transplant (p=0.023). Relative scores were highly significant, but did not change the results using absolute scores at any time point. Conclusions: MIBG scoring is a useful tool in identifying pts with extremely poor prognosis following induction therapy. Patients with a Curie score > 5 after induction have a 3 yr EFS < 10%, and should be considered for alternative therapy regimen. No significant financial relationships to disclose.
Outcomes of retesting <i>BRCA</i>-negative patients using multigene panels.
Authors: Siddhartha Yadav, Jennifer Fulbright, Heidi Dreyfuss, Ashley Reeves, Sarah Campian, Vicky Thomas, Dana Zakalik
Journal: Journal of Clinical Oncology (2015)

23 Background: New technologies for identifying hereditary predisposition to breast cancer have led to the discovery of novel genes associated with cancer risk. This has prompted re-evaluation of patients who previously tested negative for BRCA1/2 gene mutations, with a possibility of discovering new genes which may impact management. This study reports on the results of retesting patients who previously were negative for BRCA1/2. Methods: Patients who tested negative for BRCA1/2 mutations who had significant personal and family history were referred back to the Cancer Genetics Center between February 1, 2012 and May 30, 2105 for discussion of additional testing. A detailed personal and family history was reviewed, and patients were counseled about the genetics and clinical implications of panel testing for multiple breast cancer genes. Panel testing using next generation sequencing technologies was ordered. Patients were seen in follow up for discussion of results and management. Results: A total of 12 pathogenic mutations were identified during the study period. The genes and frequencies of these mutations were: CHEK2(3), PALB2(3), ATM(2), APC(1), BARD(1), CDH(1), MUTYH(1). There were 33 variants of undetermined significance(VUS) in 27 patients. 5 of these were seen in patients with a known pathogenic mutation; 3 others were later classified as benign. The frequencies of these VUSs were: ATM (9), PALB2(3), BARD1 (3), PTEN(3), PMS2(3), MSH6(2), CHEK2 (1), MYH(1), RAD51(1), BRIP1(2), NF1(1), BMPR1A(1). Of the 46 patients who had their initial BRCA testing and repeat panel testing between February 1, 2012 and May 30, 2015, 6 (13%) tested positive for a pathogenic mutation. Conclusions: This study demonstrates the feasibility and potential clinical benefit of retesting individuals who previously tested negative for BRCA1/2 mutation. This approach had a significant management impact on patients and their families, with a 13% detection rate of pathogenic mutations. The success of retesting is predicated upon an infrastructure of provider and patient education, pre and post genetic counseling and serves as a model for other centers.
Abstract 14046: Heparin Alone is Not Enough. Gp IIb/IIIa Inhibitors Improve Outcome in Patients With Primary PCI for STEMI Treated With Heparin. Results of the Prospective ALKK-Registry
Authors: Uwe Zeymer, Matthias Hochadel, Anselm Gitt, Dietrich Andresen, Ralf Zahn
Journal: Circulation (2014)

Background: There is still debate about the optimal antithrombotic therapy in patients undergoing primary PCI. Earlier randomized trials have shown a benefit of GP IIb/IIIa inhibitors in patients treated with heparin, with the highest benefit in high risk patients. Most recent trials did not support the earlier data. Therefore we evaluated the impact of GP IIb/IIIa inhibitors on outcome in patients with primary PCI for STEMI in real life in a large number of patients. Methods: We used the data of the ongoing prospective ALKK-PCI registry and included patients with PCI for STEMI &lt; 24 h duration treated with heparin in 40 centres. We excluded patients who were treated with bivalirudin. Results: Between 2008 and 2012 a total of 15061 consecutive patients with PCI for STEMI without cardiogenic shock were included. Of these 8864 (58.9 %) received a GP IIb/IIIa inhibitor. Baseline characteristics, procedural features and in-hospital outcomes are given in the table. In a multivariate analysis GP IIb/IIIa inhibitors were associated with a reduced mortality (odds ratio 0.81, 95% CI 0.72-0.96). Conclusion: In clinical practice GP IIb/IIIa inhibitors are used in more than 50% of the patients with primary PCI for STEMI treated with heparin. The use is associated with an improved mortality without an increase in bleeding complications. This data support the results of randomized clinical trials and questions the use of heparin alone as intravenous antithrombotic agent.
Phase Ib Trial of Nab-Paclitaxel Plus Gemcitabine, Capecitabine, and Cisplatin (Paxg Regimen) in Patients with Stage III Pancreatic Adenocarcinoma
Authors: M. Reni, C. Belli, G. Balzano, S. Cereda, R. Nicoletti, G. Pepe, C. Sessa, S. Cappio, C. Doglioni, V. Palazzo, D. Ceraulo, L. Gianni
Journal: Annals of Oncology (2014)
Adherence to acne treatment guidelines in the military environment - a descriptive, serial cross-sectional study
Authors: Chen Fleischmann, Lior Cohen, Elimelech Adams, Michael Hartal
Journal: Military Medical Research (2015)

Acne vulgaris, a common skin disease, affects up to 80 % of the population. Moderate to severe acne requires treatment with a combination of topical and oral drugs such as antibiotics, hormones and retinoids. Retinoids have many contraindications and adverse effects requiring close monitoring. The study's objectives were to describe prescribing trends in acne medication over time in a military setting, and assess physician adherence to guidelines for acne treatment, including drug precautions, clinical monitoring, and treatment progression.We conducted a descriptive, serial cross-sectional study of acne drugs prescribed in the Israel Defense Forces (IDF) in the years 2002-2007, analyzing the classes of drugs prescribed and patient characteristics. In addition, the clinical quality of the medical encounter was assessed by examining physician adherence to IDF guidelines.Between 2002 and 2007, 64,281 patients were treated for acne. Treatment courses generally persisted for 1-2 months. Over 70 % of female patients receiving oral retinoids were not concomitantly receiving oral contraceptives.This study provides a unique perspective of acne treatment in a military setting, overall displaying good adherence to general guidelines. The common prescription of oral retinoids to young females without concomitant contraception is alarming.
Pulmonary hypertension in end-stage renal disease and post renal transplantation patients
Authors: Esam H. Alhamad, Joseph H. Cal, Hussam F. Alfaleh, Mohammed Al-Ghonaim, Nazmi Said
Journal: European Respiratory Journal (2013)

Background: Information regarding lung function parameters and functional capacity in renal failure and post renal transplantation patients with pulmonary hypertension (PH) is limited. The purpose of this study was to examine the clinical characteristics of patients with PH who were receiving hemodialysis (HD) or peritoneal dialysis (PD) or who had undergone renal transplantation. Methods: A prospective study was performed on 116 patients (HD =55, PD =17, and post renal transplantation =44) who underwent Doppler echocardiography. PH was defined as systolic pulmonary artery pressure (SPAP) ≥40 mmHg. Demographic information, clinical characteristics, pulmonary function tests (PFTs) and the six-minute walk test (6MWT) were collected and compared between the patients with and without PH. Results: Twelve (21.8%) patients receiving HD, four (23.5%) patients receiving PD, and eight (18.2%) post renal transplantation patients had PH. In the HD group, the physiological indicators (including pulmonary function test parameters, the final Borg score, and walking distance during the 6MWT) were all significantly lower in the patients with PH compared with those without PH (all P 0.05). Conclusions: Among HD patients, marked aberrations in PFT results or walking distance may identify a subset of patients suffering from PH.
Heterogeneity of Psychosis Risk Within Individuals at Clinical High Risk
Authors: Paolo Fusar-Poli, Marco Cappucciati, Stefan Borgwardt, Scott W. Woods, Jean Addington, Barnaby Nelson, Dorien H. Nieman, Daniel R. Stahl, Grazia Rutigliano, Anita Riecher-Rössler, Andor E. Simon, Masafumi Mizuno, Tae Young Lee, Jun Soo Kwon, May M. L. Lam, Jesus Perez, Szabolcs Keri, Paul Amminger, Sibylle Metzler, Wolfram Kawohl, Wulf Rössler, Jimmy Lee, Javier Labad, Tim Ziermans, Suk Kyoon An, Chen-Chung Liu, Kristen A. Woodberry, Amel Braham, Cheryl Corcoran, Patrick McGorry, Alison R. Yung, Philip K. McGuire
Journal: JAMA Psychiatry (2015)

Individuals can be classified as being at clinical high risk (CHR) for psychosis if they meet at least one of the ultra-high-risk (UHR) inclusion criteria (brief limited intermittent psychotic symptoms [BLIPS] and/or attenuated psychotic symptoms [APS] and/or genetic risk and deterioration syndrome [GRD]) and/or basic symptoms [BS]. The meta-analytical risk of psychosis of these different subgroups is still unknown.To compare the risk of psychosis in CHR individuals who met at least one of the major inclusion criteria and in individuals not at CHR for psychosis (CHR-).Electronic databases (Web of Science, MEDLINE, Scopus) were searched until June 18, 2015, along with investigation of citations of previous publications and a manual search of the reference lists of retrieved articles.We included original follow-up studies of CHR individuals who reported the risk of psychosis classified according to the presence of any BLIPS, APS and GRD, APS alone, GRD alone, BS, and CHR-.Independent extraction by multiple observers and random-effects meta-analysis of proportions. Moderators were tested with meta-regression analyses (Bonferroni corrected). Heterogeneity was assessed with the I2 index. Sensitivity analyses tested robustness of results. Publication biases were assessed with funnel plots and the Egger test.The proportion of each subgroup with any psychotic disorder at 6, 12, 24, 36, and 48 or more months of follow-up.Thirty-three independent studies comprising up to 4227 individuals were included. The meta-analytical proportion of individuals meeting each UHR subgroup at intake was: 0.85 APS (95%CI, 0.79-0.90), 0.1 BLIPS (95%CI, 0.06-0.14), and 0.05 GRD (95%CI, 0.03-0.07). There were no significant differences in psychosis risk at any time point between the APS and GRD and the APS-alone subgroups. There was a higher risk of psychosis in the any BLIPS greater than APS greater than GRD-alone subgroups at 24, 36, and 48 or more months of follow-up. There was no evidence that the GRD subgroup has a higher risk of psychosis than the CHR- subgroup. There were too few BS or BS and UHR studies to allow robust conclusions.There is meta-analytical evidence that BLIPS represents separate risk subgroup compared with the APS. The GRD subgroup is infrequent and not associated with an increased risk of psychosis. Future studies are advised to stratify their findings across these different subgroups. The CHR guidelines should be updated to reflect these differences.
Abstract 9764: Clinical Characteristics and Temporal Trends Among Patients Presenting Late (&gt;12 Hours After Symptom Onset) With ST-Elevation Myocardial Infarction - A Report From the NCDR®
Authors: Praneet K Sharma, Matthew T Roe, Faraz Kureshi, DaJuanicia N Holmes, Brahmajee K Nallamothu, David J Cohen
Journal: Circulation (2014)

Background: Late presentation after ST-elevation myocardial infarction (STEMI) is associated with poor outcomes. However, contemporary data regarding management and outcomes of such patients are lacking. Methods: Using data from the ACTION Registry-GWTG, we identified 170,247 patients who presented with STEMI to 688 US sites, between 7/08 and 12/13. Patients were stratified according to time from symptom onset to presentation as timely presenters (&lt;12 hours) and late presenters (≥12 hours). Baseline characteristics, management and in-hospital outcomes were compared between the groups. Among late presenters, temporal trends in reperfusion strategy were also examined. Results: A total of 9389 patients (5.5%) had late presentation and 160,858 (94.5%) had timely presentation. Late presenters were more frequently elderly, female and of non-White ethnicity (Table). Late presenters were less likely to have prior MI or prior revascularization, but more likely to have diabetes. Compared with timely presenters, late presenters had worse in-hospital outcomes including mortality (6.3% vs. 5.2%; p&lt;0.0001). Over the 6-year study period, the proportion of late presenters decreased slightly (5.8 vs. 5.4% respectively; p=0.03), while the proportion of late presenters undergoing primary PCI increased from 65% to 71% (p&lt;0.001). Over the same time-period, among late presenters, median time from symptom onset to presentation increased slightly, door to balloon time decreased, and in-hospital mortality remained unchanged (6.0% vs. 6.0%). Conclusions: In contemporary practice, a modest proportion of STEMI patients continue to present &gt;12 hours after symptom onset. Despite increased use of primary PCI and reduction in door-to-balloon times, the unadjusted mortality remains high among late presenters. Continued efforts to educate the public in order to reduce the proportion of late presenters remains warranted.
The Consult Guys - Excluding the Diagnosis of Pulmonary Embolism: Is There a Magic Ball?
Authors: Geno J. Merli, Howard H. Weitz
Journal: Annals of Internal Medicine (2015)

Web Exclusives15 December 2015The Consult Guys - Excluding the Diagnosis of Pulmonary Embolism: Is There a Magic Ball?FREEGeno J. Merli, MD and Howard H. Weitz, MDGeno J. Merli, MDSearch for more papers by this author and Howard H. Weitz, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/W15-0011 SectionsSupplemental MaterialAboutVisual Abstract ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail The Consult Guys bring a new perspective to the art and science of medicine with lively discussion and analysis of real-world cases and situations.For more videos from and information on The Consult Guys, visit www.annals.org/ConsultGuys. Comments0 CommentsSign In to Submit A Comment Author, Article, and Disclosure InformationAffiliations: Disclosures: Geno J. Merli, MD, reports the following: Research grants/contracts: Bristol-Myers Squibb, Janssen, Portola; Consultancies: Bristol-Myers Squibb, Janssen. Howard H. Weitz, MD, reports that he has no financial relationships or interests to disclose. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 15 December 2015Volume 163, Issue 12Page: CG1KeywordsDisclosurePulmonary embolismResearch grantsResearch reporting guidelines ePublished: 15 December 2015 Issue Published: 15 December 2015 Copyright & PermissionsCopyright © 2015 by American College of Physicians. All Rights Reserved.Loading ...